CSE AIML | OTCQB AIMLF | FWB 42FB
PRESS RELEASE

AIML Innovations Announces Departure of Tim Daniels from Board of Directors

April 25, 2025

• Tim Daniels to Continue Supporting AIML in an Advisory Capacity

Vancouver, Canada – April 25, 2025AI/ML Innovations Inc. (“AIML” or the “Company”) (CSE: AIML;OTCQB: AIMLF; FWB: 42FB) announces that Tim Daniels has stepped down from his position on the Company’s Board of Directors (“Board”), effective immediately.

Tim has been an integral part of AIML’s leadership, contributing to the Company’s strategic direction and governance during his tenure on the Board. His insights and dedication have played a key role in guiding AIML through important phases of growth and evolution.

Paul Duffy, CEO of AIML, commented:

“On behalf of the entire team at AIML, I would like to extend our sincere thanks to Tim for his contributions and leadership. We are pleased that Tim will continue to support the Company in an advisory capacity, where his experience and counsel will remain a valued asset as we advance our mission in AI-driven healthcare.”

AIML remains focused on strengthening its leadership and advisory network to support ongoing commercialization efforts and strategic growth initiatives.

For more information about AIML:

For detailedinformation please see AIML's website or the Company's filed documents at www.sedarplus.ca.

Contact:  

Blake Fallis  

(778) 405-0882  

info@aiml-innovations.com

AboutAI/ML Innovations Inc. https://aiml-innovations.com/

AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its wholly owned subsidiaries, NeuralCloud Solutions Inc. (theneuralcloud.com), Quantum Sciences Ltd, and AI Rx Inc., strategic partnerships with HealthGauge Inc. (95.2% owned by AIML), and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AIML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

On behalf of the Board of Directors:

Paul Duffy, Chairman 

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements – Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

Read More

June 10, 2025
AIML Strengthens IP Portfolio with Provisional Patents for AI Driven ECG Signal Processing
Read More
June 3, 2025
AIML Subsidiary Neural Cloud Signs LOI with Circular Health to License MaxYield™ ECG Signal-Processing
Read More
May 22, 2025
AIML Establishes Innovation Committee, Appoints Dr. Drew Dundas as Chair
Read More
May 20, 2025
AIML Establishes Medical Advisory Board to Drive AI Powered ECG Signal Processing Innovation
Read More
May 15, 2025
AIML Hits Key Regulatory Benchmark with 510(k) Filing for MaxYield™ Signal Enhancement Platform
Read More
May 5, 2025
AIML Innovations Appoints Political Strategist and Public Affairs Leader, Michael Diamond, to Board of Directors
Read More
April 25, 2025
AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Read More
April 25, 2025
AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Read More
April 22, 2025
AIML Innovations Appoints Jared Adelstein to Board of Directors
Read More
April 15, 2025
AIML Announces Closing of Oversubscribed Private Placement
Read More
April 7, 2025
AIML Updates Terms of Proposed Private Placement Announced
Read More
April 4, 2025
AIML Announces Proposed Private Placement
Read More
January 9, 2025
AI/ML Innovations Inc. Welcomes Industry Trailblazers to Board of Directors
Read More
January 23, 2025
AI/ML Innovations Inc. Appoints Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships
Read More
January 28, 2025
Andrea Ruth Joins AI/ML Innovations as Head of Quality, Clinical, and Regulatory Affairs
Read More
February 20, 2025
Key Updates to Upcoming Annual and Special Meeting
Read More
March 14, 2025
AIML Aligns Leadership for Growth and Shareholder Value Creation
Read More
March 21, 2025
AIML Continues to Streamline for the Future and Moves Beyond Tech2Heal
Read More